Published on 24/12/2025
Post-Authorization Safety Studies in the European Union
Post-Authorization Safety Studies (PASS) are a cornerstone of the European Union’s pharmacovigilance framework. Conducted after a medicinal product has received marketing authorization, PASS are designed to monitor the product’s safety in real-world use, identify potential new risks, and quantify known risks in diverse patient populations. In the EU, PASS are regulated under Directive 2001/83/EC, Regulation (EC) No 726/2004, and subsequent pharmacovigilance legislation, with oversight by the European Medicines Agency (EMA) and the Pharmacovigilance Risk Assessment Committee (PRAC). They may be imposed as part of a Risk Management Plan (RMP) or voluntarily initiated by marketing authorization holders (MAHs).
This article explores the regulatory framework, operational requirements, and best practices for conducting PASS in the EU, highlighting their role in ensuring patient safety and regulatory compliance.
Background and Regulatory Framework
Legal Basis for PASS
PASS obligations in the EU stem from Directive 2001/83/EC and Regulation (EC) No 726/2004. Amendments introduced by the 2010 Pharmacovigilance Legislation reinforced EMA’s authority to impose mandatory PASS where safety concerns exist.
EMA and PRAC Oversight
The Pharmacovigilance Risk Assessment Committee (PRAC) at EMA reviews and endorses PASS protocols, monitors study conduct, and evaluates results. PRAC ensures PASS are scientifically rigorous
Types of PASS
PASS may be:
- Imposed PASS: Required as a condition of marketing authorization.
- Voluntary PASS: Conducted by MAHs proactively to enhance product safety profiles.
- Non-Interventional PASS: Observational studies, registries, or database analyses.
- Interventional PASS: Trials specifically designed to address safety concerns.
Core Clinical Trial Insights: Conducting PASS
1. Protocol Approval and Transparency
All EU PASS protocols must be submitted through the EU PAS Register, which is maintained by EMA and accessible to the public. Protocols require PRAC approval, and final study reports must also be uploaded to ensure transparency.
2. PASS and Risk Management Plans
PASS are often linked to RMPs as commitments to regulators. These studies help evaluate specific safety concerns identified during development or post-marketing surveillance.
3. PASS Design Considerations
Study design depends on the safety issue being investigated. Common designs include:
- Prospective observational studies
- Patient registries
- Electronic health record (EHR) analyses
- Retrospective database studies
4. Reporting Obligations
MAHs must submit interim and final PASS results to EMA and NCAs. Results are evaluated by PRAC and may lead to updated labeling, risk minimization measures, or regulatory actions if safety concerns are confirmed.
5. Role of CROs
CROs are frequently engaged to design and execute PASS. They manage study logistics, data collection, and compliance with GCP and GVP standards. Sponsors must maintain oversight through contractual agreements and audits.
6. PASS in Real-World Evidence (RWE)
PASS increasingly leverage real-world data (RWD) sources such as EHRs, insurance databases, and patient registries. These approaches improve efficiency but require robust data governance and GDPR compliance.
7. PASS Inspections
EMA and NCAs inspect PASS to ensure protocol adherence, data quality, and proper pharmacovigilance reporting. Common findings include incomplete data capture, delayed reporting, and weak sponsor oversight.
8. PASS in Special Populations
PASS often focus on populations underrepresented in pre-authorization trials, such as pediatrics, geriatrics, and pregnant women, to identify unique safety concerns.
Best Practices & Preventive Measures
- Engage early with PRAC when designing PASS protocols.
- Ensure transparency by registering all PASS in the EU PAS Register.
- Adopt robust data collection systems compliant with GDPR and GVP Module VIII.
- Implement clear sponsor-CRO oversight mechanisms.
- Plan interim analyses to detect early safety signals.
Scientific and Regulatory Evidence
- Directive 2001/83/EC
- Regulation (EC) No 726/2004
- EU Pharmacovigilance Legislation 2010
- Good Pharmacovigilance Practices (GVP) Module VIII
- EMA EU PAS Register Guidance
Special Considerations
PASS requirements vary based on therapeutic area and product profile:
- Oncology: Long-term follow-up PASS required for monitoring late-onset toxicities.
- Rare Diseases: PASS leverage EU registries to capture data across dispersed patient populations.
- ATMPs: Gene and cell therapies often require PASS extending over a decade to monitor delayed effects.
- Pediatrics: PASS complement Pediatric Investigation Plans (PIPs) to ensure safety monitoring.
When Sponsors Should Seek Regulatory Advice
- When PRAC-mandated PASS protocols involve complex designs or new methodologies.
- If leveraging novel RWD sources for PASS execution.
- When planning PASS for high-risk products like ATMPs.
- Before submitting final PASS results that may trigger label changes.
- In rare diseases where data scarcity requires innovative approaches.
FAQs
1. What is the purpose of PASS in the EU?
PASS are designed to monitor the safety of authorized medicines in real-world use and evaluate identified or potential risks.
2. Who oversees PASS in the EU?
The EMA’s PRAC reviews protocols, monitors conduct, and evaluates results to guide regulatory action.
3. Are PASS mandatory?
Yes, when imposed as a condition of authorization. Sponsors may also conduct voluntary PASS to strengthen safety data.
4. What is the EU PAS Register?
An EMA-managed public database where PASS protocols and results must be uploaded to ensure transparency.
5. Do PASS require ethics approval?
Yes. Even though many PASS are non-interventional, they require ethics review in participating Member States.
6. How long do PASS last?
Duration varies, from short-term observational studies to decade-long follow-ups, particularly for ATMPs.
7. What happens if PASS reveal new safety concerns?
Findings may lead to label changes, risk minimization measures, or regulatory restrictions on product use.
Conclusion
Post-Authorization Safety Studies are critical for maintaining patient safety and public trust in the EU pharmacovigilance system. By systematically monitoring real-world use, PASS provide valuable evidence that complements pre-authorization data. Sponsors who engage early with PRAC, leverage high-quality real-world data, and ensure compliance with GVP Module VIII can not only meet regulatory obligations but also strengthen benefit-risk assessments and enhance the credibility of their products in the EU market.